Literature DB >> 30941644

Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.

Dorra BenAyed-Guerfali1, Emna Dabbèche-Bouricha1, Wajdi Ayadi1, Fatma Trifa2, Slim Charfi3, Abdelmajid Khabir4, Tahia Sellami-Boudawara3, Raja Mokdad-Gargouri5.   

Abstract

The transcription factor FOXA1 (forkhead box A1) plays key roles in tumor development and progression. In the present study, we analyzed the expression of FOXA1 in 52 breast tumors and 10 normal tissues, and investigated the relationship between FOXA1 and two EMT markers, namely Twist1 and E-cadherin by RT-PCR and IHC respectively. The expression level of FOXA1 was higher in tumor compared to normal tissues but the difference was not statistically significant (P = 0.138). FOXA1 expression correlated with less aggressive behavior as SBR grade I (P = 0.04), small tumors size (P = 0.05), and longer survival (P = 0.001). Furthermore, estrogen and progesterone positive tumors exhibit high level of FOXA1 (P = 0.002 and P = 0.038 respectively). Survival analysis showed that patients with ER positive/FOXA1 positive (P log rank = 0.001), PR positive/FOXA1 positive (P log rank = 0.044) and HER-2 negative/FOXA1 positive (P log rank = 0.002) tumors have a significant prolonged overall survival. On the other hand, the expression of E-cadherin positively correlated with FOXA1 (P = 0.028), whereas negative association was seen between the expression of Twist1 and FOXA1 (P = 0.016). Kaplan-Meier plots showed that patients with Twist1negative/FOXA1positive tumors have a significant prolonged overall survival (P log rank = 0.001) and FOXA1 appeared as independent predictors of patient survival in multivariate analyses. Overall, our results indicate that FOXA1 could be a useful biomarker to predict prognosis in breast cancer patients.

Entities:  

Keywords:  Biomarker; Breast cancer; Epithelial to mesenchymal transition; Immunohistochemistry

Mesh:

Substances:

Year:  2019        PMID: 30941644     DOI: 10.1007/s11033-019-04784-w

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

Review 1.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 2.  The emerging roles of forkhead box (Fox) proteins in cancer.

Authors:  Stephen S Myatt; Eric W-F Lam
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

3.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Authors:  Balazs Györffy; Andras Lanczky; Aron C Eklund; Carsten Denkert; Jan Budczies; Qiyuan Li; Zoltan Szallasi
Journal:  Breast Cancer Res Treat       Date:  2009-12-18       Impact factor: 4.872

4.  Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.

Authors:  Yuichi Hisamatsu; Eriko Tokunaga; Nami Yamashita; Sayuri Akiyoshi; Satoko Okada; Yuichiro Nakashima; Shinichi Aishima; Masaru Morita; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2011-10-08       Impact factor: 5.344

5.  Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.

Authors:  Jason S Carroll; X Shirley Liu; Alexander S Brodsky; Wei Li; Clifford A Meyer; Anna J Szary; Jerome Eeckhoute; Wenlin Shao; Eli V Hestermann; Timothy R Geistlinger; Edward A Fox; Pamela A Silver; Myles Brown
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

6.  Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Yan Song; M Kay Washington; Howard C Crawford
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

7.  The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas.

Authors:  Lin Lin; Charles T Miller; Jorge I Contreras; Michael S Prescott; Susan L Dagenais; Rong Wu; John Yee; Mark B Orringer; David E Misek; Samir M Hanash; Thomas W Glover; David G Beer
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

8.  FOXA1 Induces E-Cadherin Expression at the Protein Level via Suppression of Slug in Epithelial Breast Cancer Cells.

Authors:  Erina Anzai; Kensuke Hirata; Misato Shibazaki; Chiaki Yamada; Mariko Morii; Takuya Honda; Naoto Yamaguchi; Noritaka Yamaguchi
Journal:  Biol Pharm Bull       Date:  2017       Impact factor: 2.233

Review 9.  FOXA1: a promising prognostic marker in breast cancer.

Authors:  Qing Hu; Zhou Luo; Tao Xu; Jun-Ying Zhang; Ying Zhu; Wei-Xian Chen; Shan-Liang Zhong; Jian-Hua Zhao; Jin-Hai Tang
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 10.  FOXA1 in breast cancer.

Authors:  Harikrishna Nakshatri; Sunil Badve
Journal:  Expert Rev Mol Med       Date:  2009-03-05       Impact factor: 5.600

View more
  8 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 2.  Forkhead Box Transcription Factors: Double-Edged Swords in Cancer.

Authors:  Maria Castaneda; Petra den Hollander; Sendurai A Mani
Journal:  Cancer Res       Date:  2022-06-06       Impact factor: 13.312

Review 3.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

4.  NEDD4 triggers FOXA1 ubiquitination and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation.

Authors:  Meng Yue; Zhennan Yun; Shiquan Li; Guoqiang Yan; Zhenhua Kang
Journal:  RNA Biol       Date:  2021-02-11       Impact factor: 4.652

5.  FOXA1 Expression in Nasopharyngeal Carcinoma: Association with Clinicopathological Characteristics and EMT Markers.

Authors:  Nihel Ammous-Boukhris; Wajdi Ayadi; Mariem Derbel; Nesrine Allaya-Jaafar; Slim Charfi; Jamel Daoud; Tahya Sellami-Boudawara; Raja Mokdad-Gargouri
Journal:  Biomed Res Int       Date:  2020-06-22       Impact factor: 3.411

6.  Ready and Waiting: Where Early-Stage Idiopathic Pulmonary Fibrosis Fibroblasts Are Primed to Be Activated.

Authors:  John E McDonough
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 6.914

7.  Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.

Authors:  Sanghoon Lee; Hatice Ulku Osmanbeyoglu
Journal:  Breast Cancer Res       Date:  2022-07-29       Impact factor: 8.408

8.  miR‑132 is upregulated in polycystic ovarian syndrome and inhibits granulosa cells viability by targeting Foxa1.

Authors:  Xiangrong Cui; Xuan Jing; Junfen Liu; Xingyu Bi; Xueqing Wu
Journal:  Mol Med Rep       Date:  2020-10-14       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.